Active Low-Carber Forums
Atkins diet and low carb discussion provided free for information only, not as medical advice.
Home Plans Tips Recipes Tools Stories Studies Products
Active Low-Carber Forums
A sugar-free zone


Welcome to the Active Low-Carber Forums.
Support for Atkins diet, Protein Power, Neanderthin (Paleo Diet), CAD/CALP, Dr. Bernstein Diabetes Solution and any other healthy low-carb diet or plan, all are welcome in our lowcarb community. Forget starvation and fad diets -- join the healthy eating crowd! You may register by clicking here, it's free!

Go Back   Active Low-Carber Forums > Main Low-Carb Diets Forums & Support > Countdowns, Buddies & Challenges
User Name
Password
FAQ Members Calendar Search Gallery My P.L.A.N. Survey


Reply
 
Thread Tools Display Modes
  #1651   ^
Old Sat, Aug-19-17, 09:08
Zuleikaa Zuleikaa is offline
Finding the Pieces
Posts: 17,049
 
Plan: Mishmash
Stats: 365/308.0/185 Female 66
BF:
Progress: 32%
Location: Maryland, US
Default

Topical vitamin D3 derivatives in treating hyperkeratotic palmoplantar eczema: a report of five patients.
Egawa K1.
Author information


Abstract
The treatment of hyperkeratotic palmoplantar eczema is notoriously difficult. A considerable number of patients do not or only partially respond to the current treatments such as topical corticosteroids, topical keratolytics, or PUVA therapy. The purpose of this pilot study was to look for an alternative treatment for hyperkeratotic palmoplantar eczema. We treated five patients with topical vitamin D3 derivatives (calcipotriol 50 microg/g and maxacalcitol 25 microg/g ointments). The lesions almost disappeared after 2 to 8 weeks of treatment in four patients and extremely improved with a seven week treatment in one patient. No adverse effect was observed during or after the treatment, and routine laboratory investigations were within normal ranges. When relapses occurred, they responded well to retreatment. Although the study is preliminary, the results suggest that vitamin D3 derivatives offer a safe, effective alternative form of treatment for recalcitrant hyperkeratotic palmoplantar eczema.

https://www.ncbi.nlm.nih.gov/pubmed/16043902
Reply With Quote
Sponsored Links
  #1652   ^
Old Sat, Aug-19-17, 17:40
Zuleikaa Zuleikaa is offline
Finding the Pieces
Posts: 17,049
 
Plan: Mishmash
Stats: 365/308.0/185 Female 66
BF:
Progress: 32%
Location: Maryland, US
Default

Patients with Nonalcoholic Fatty Liver Disease Have a Low Response Rate to Vitamin D Supplementation.
Dasarathy J1, Varghese R1, Feldman A1, Khiyami A2, McCullough AJ3, Dasarathy S4.
Author information


Abstract
Background: Hypovitaminosis D is associated with an increased severity of nonalcoholic fatty liver disease (NAFLD), but reports on the response to cholecalciferol (vitamin D3) supplementation are conflicting.Objective: The objective of this study was to determine if standard vitamin D3 supplementation is effective in NAFLD with hypovitaminosis D.Methods: Sixty-five well-characterized adults [age (mean ± SD): 51.6 ± 12.3 y] with biopsy-proven NAFLD were screened. Forty-two patients (the ratio of men to women was 13:29) had hypovitaminosis D (plasma 25-hydroxyvitamin D [25(OH)D] <30 ng/mL). An observational study was performed in NAFLD patients with hypovitaminosis D treated with 2000 IU cholecalciferol (vitamin D3) daily for 6 mo per clinical practice. Plasma 25(OH)D, hepatic and metabolic panels, and metabolic syndrome components were assessed before and after cholecalciferol supplementation. Body composition was measured by using bioelectrical impedance analysis. The primary outcome measure was plasma 25(OH)D ≥30 ng/mL at the end of the study. Secondary outcomes included change in serum transaminases, fasting plasma glucose, and insulin and homeostasis model assessment of insulin resistance (HOMA-IR). Chi-square, Student's t tests, correlation coefficient, and multivariate analysis were performed.Results: Twenty-six (61.9%) patients had nonalcoholic steatohepatitis (NASH), and 16 (38.1%) had hepatic steatosis. After 6 mo of cholecalciferol supplementation, plasma 25(OH)D ≥30 ng/mL was observed in 16 subjects (38.1%; responders) whereas the remaining 26 patients (61.9%) were nonresponders with plasma 25(OH)D <30 ng/mL. Significantly fewer (P < 0.01) patients with NASH were responders (4 of 26, 15.4%) than those with hepatic steatosis (12 of 16, 75%). Baseline fasting serum alanine aminotransferase, plasma glucose, and HOMA-IR were similar in the responders and nonresponders, but the NASH score on the liver biopsy was lower (16.5%) in the responders (P < 0.001). Nonresponders had a higher fat mass (10.5%) and lower fat-free mass (10.4%) than responders did. End-of-treatment alanine aminotransferase and HOMA-IR improved only in responders. The baseline HOMA-IR and histological NASH score were independent predictors of nonresponse to cholecalciferol supplementation.Conclusions: Daily supplementation with 2000 IU cholecalciferol for 6 mo did not correct hypovitaminosis D in the majority of patients with NASH. Further studies are needed to determine if higher doses are effective. This trial was registered at clinicaltrials.gov as 13-00153.

https://www.ncbi.nlm.nih.gov/pubmed/28814531
Reply With Quote
  #1653   ^
Old Sat, Aug-19-17, 17:41
Zuleikaa Zuleikaa is offline
Finding the Pieces
Posts: 17,049
 
Plan: Mishmash
Stats: 365/308.0/185 Female 66
BF:
Progress: 32%
Location: Maryland, US
Default

Effect of vitamin D supplementation in chronic widespread pain: a systematic review and meta-analysis.
Yong WC1, Sanguankeo A2,3, Upala S2,3.
Author information


Abstract
Chronic non-specific widespread pain (CWP) including fibromyalgia (FMS) is characterized by widespread pain, reduced pain threshold, and multiple tender points on examination, causing disability and decreased quality of life. Vitamin D has been proposed as an associated factor in CWP. This meta-analysis aimed to explore the benefit of vitamin D supplementation in the management of CWP. A comprehensive search of the CENTRAL, MEDLINE, and Embase databases was performed from inception through January 2017. The inclusion criterion was the randomized clinical trials' evaluating the effects of vitamin D treatment in adult subjects with CWP or FMS. CWP was defined as chronic recurrent musculoskeletal pain without secondary causes; FMS patients met the American College of Rheumatology criteria for FMS. Study outcome was assessed using visual analog scale (VAS) of pain intensity. Pooled mean difference (MD) of VAS and 95% confidence interval (CI) were calculated using a random-effect meta-analysis. Meta-regression analysis using a random-effects model was performed to explore the effects of change in vitamin D in the treatment group on difference in the mean of VAS. Sensitivity analysis was performed to evaluate the robustness of results. The between-study heterogeneity of effect size was quantified using the Q statistic and I 2. Data were extracted from four randomized controlled trials involving 287 subjects. Pooled result demonstrated a significantly lower VAS in CWP patients who received vitamin D treatment compared with those who received placebo (MD~=~0.46; 95% CI 0.09-0.89, I 2~=~48%). Meta-regression analysis revealed no significant relationship between the changes of vitamin D and VAS (coefficient~=~0.04 (95% CI -0.01 to 0.08), p~=~0.10). In this meta-analysis, we conclude that vitamin D supplementation is able to decrease pain scores and improve pain despite no significant change in VAS after increasing serum vitamin D level. Further studies need to be conducted in order to explore the improvement of functional status, quality of life, and the pathophysiological change that improves chronic widespread pain.

https://www.ncbi.nlm.nih.gov/pubmed/28812209
Reply With Quote
  #1654   ^
Old Sat, Aug-19-17, 17:44
Zuleikaa Zuleikaa is offline
Finding the Pieces
Posts: 17,049
 
Plan: Mishmash
Stats: 365/308.0/185 Female 66
BF:
Progress: 32%
Location: Maryland, US
Default

The Big Vitamin D Mistake.
Papadimitriou DT1,2.
Author information


Abstract
Since 2006, type 1 diabetes in Finland has plateaued and then decreased after the authorities' decision to fortify dietary milk products with cholecalciferol. The role of vitamin D in innate and adaptive immunity is critical. A statistical error in the estimation of the recommended dietary allowance (RDA) for vitamin D was recently discovered; in a correct analysis of the data used by the Institute of Medicine, it was found that 8895 IU/d was needed for 97.5% of individuals to achieve values ≥50 nmol/L. Another study confirmed that 6201 IU/d was needed to achieve 75 nmol/L and 9122 IU/d was needed to reach 100 nmol/L. The largest meta-analysis ever conducted of studies published between 1966 and 2013 showed that 25-hydroxyvitamin D levels <75 nmol/L may be too low for safety and associated with higher all-cause mortality, demolishing the previously presumed U-shape curve of mortality associated with vitamin D levels. Since all-disease mortality is reduced to 1.0 with serum vitamin D levels ≥100 nmol/L, we call public health authorities to consider designating as the RDA at least three-fourths of the levels proposed by the Endocrine Society Expert Committee as safe upper tolerable daily intake doses. This could lead to a recommendation of 1000 IU for children <1 year on enriched formula and 1500 IU for breastfed children older than 6 months, 3000 IU for children >1 year of age, and around 8000 IU for young adults and thereafter. Actions are urgently needed to protect the global population from vitamin D deficiency.

https://www.ncbi.nlm.nih.gov/pubmed/28768407
Reply With Quote
  #1655   ^
Old Thu, Aug-24-17, 07:56
Zuleikaa Zuleikaa is offline
Finding the Pieces
Posts: 17,049
 
Plan: Mishmash
Stats: 365/308.0/185 Female 66
BF:
Progress: 32%
Location: Maryland, US
Default

Vitamin D and pancreatic cancer.

Barreto SG1, Neale RE2.



Author information


Abstract

Pancreatic cancer is currently the fourth leading cause of cancer-related death, and it is projected that within the next two decades it will become the second most common cause of death due to cancer. Few patients are diagnosed when surgical resection is feasible and the efficacy of existing chemotherapeutic agents for advanced/metastatic cancer is limited. Thus, there is a need to identify agents that can prevent pancreatic cancer or improve survival in those affected. Vitamin D and its analogues, with their ability to regulate cell growth, differentiation, apoptosis and angiogenesis, may be promising agents. This review explores the published literature about the potential role of vitamin D and its analogues in preventing or treating pancreatic cancer. The vitamin D system is altered in pancreatic cancer. Pancreatic cancer tissue expresses vitamin D receptors, but the calcitriol analogues may affect pancreatic cancer tissue by mechanisms that do not involve interaction with its receptors. Experimental evidence postulates multiple potential mechanisms by which calcitriol analogues may exert their anti-cancer effect, the most common being by action on cyclin-dependent kinases p21 and p27. Use of calcitriol analogues in pancreatic cancer remains largely underexplored and warrants further clinical trials.

https://www.ncbi.nlm.nih.gov/pubmed/26276715
Reply With Quote
  #1656   ^
Old Thu, Aug-24-17, 07:57
Zuleikaa Zuleikaa is offline
Finding the Pieces
Posts: 17,049
 
Plan: Mishmash
Stats: 365/308.0/185 Female 66
BF:
Progress: 32%
Location: Maryland, US
Default

Calcipotriol Targets LRP6 to Inhibit Wnt Signaling in Pancreatic Cancer.

Arensman MD1, Nguyen P1, Kershaw KM1, Lay AR1, Ostertag-Hill CA1, Sherman MH2, Downes M2, Liddle C3, Evans RM4, Dawson DW5.



Author information


Abstract

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy in need of more effective treatment approaches. One potential therapeutic target is Wnt/β-catenin signaling, which plays important roles in PDAC tumor initiation and progression. Among Wnt inhibitors with suitable in vivo biologic activity is vitamin D, which is known to antagonize Wnt/β-catenin signaling in colorectal cancer and have antitumor activity in PDAC. For this study, the relationship between vitamin D signaling, Wnt/β-catenin activity, and tumor cell growth in PDAC was investigated through the use of calcipotriol, a potent non-hypercalcemic vitamin D analogue. PDAC tumor cell growth inhibition by calcipotriol was positively correlated with vitamin D receptor expression and Wnt/β-catenin activity. Furthermore, vitamin D and Wnt signaling activity were found to be reciprocally linked through feedback regulation. Calcipotriol inhibited autocrine Wnt/β-catenin signaling in PDAC cell lines in parallel with decreased protein levels of the low-density lipoprotein receptor-related protein 6 (LRP6), a requisite coreceptor for ligand-dependent canonical Wnt signaling. Decrease in LRP6 protein seen with calcipotriol was mediated through a novel mechanism involving transcriptional upregulation of low-density lipoprotein receptor adaptor protein 1 (LDLRAP1). Finally, changes in LRP6 or LDLRAP1 expression directly altered Wnt reporter activity, supporting their roles as regulators of ligand-dependent Wnt/β-catenin signaling.

IMPLICATIONS:

This study provides a novel biochemical target through which vitamin D signaling exerts inhibitory effects on Wnt/β-catenin signaling, as well as potential biomarkers for predicting and following tumor response to vitamin D-based therapy.

https://www.ncbi.nlm.nih.gov/pubmed/26224368
Reply With Quote
  #1657   ^
Old Thu, Aug-24-17, 07:59
Zuleikaa Zuleikaa is offline
Finding the Pieces
Posts: 17,049
 
Plan: Mishmash
Stats: 365/308.0/185 Female 66
BF:
Progress: 32%
Location: Maryland, US
Default

Evaluation of the potential therapeutic role of a new generation of vitamin D analog, MART-10, in human pancreatic cancer cells in vitro and in vivo.

Chiang KC1, Yeh CN, Hsu JT, Yeh TS, Jan YY, Wu CT, Chen HY, Jwo SC, Takano M, Kittaka A, Juang HH, Chen TC.



Author information


Abstract

Pancreatic cancer is a lethal disease with no known effective chemotherapy and radiotherapy, and most patients are diagnosed in the late stage, making them unsuitable for surgery. Therefore, new therapeutic strategies are urgently needed. 1α,25-dihydroxyvitamin D3 [1α,25(OH)2D3] is known to possess antitumor actions in many cancer cells in vitro and in vivo models. However, its clinical use is hampered by hypercalcemia. In this study, we investigated the effectiveness and safety of a new generation, less calcemic analog of 1α,25(OH)2D3, 19-nor-2α-(3-hydroxypropyl)-1α,25-dihydroxyvitamin D3 (MART-10), in BxPC-3 human pancreatic carcinoma cells in vitro and in vivo. We demonstrate that MART-10 is at least 100-fold more potent than 1α,25(OH)2D3 in inhibiting BxPC-3 cell proliferation in a time- and dose-dependent manner, accompanied by a greater upregulation of cyclin-dependent kinase inhibitors p21 and p27 and a greater downregulation of cyclin D3 and cyclin-dependent kinases 4 and 5, leading to a greater increase in the fraction of cells in G0/G1 phase. No induction of apoptosis and no effect on Cdc25 phosphatases A and C were observed in the presence of either MART-10 or 1α,25(OH)2D3. In a xenograft mouse model, treatment with 0.3 µg/kg body weight of MART-10 twice/week for 3 weeks caused a greater suppression of BxPC-3 tumor growth than the same dose of 1α,25(OH)2D3 without inducing hypercalcemia and weight loss. In conclusion, MART-10 is a promising agent against pancreatic cancer growth. Further clinical trial is warranted.

https://www.ncbi.nlm.nih.gov/pubmed/23549173
Reply With Quote
  #1658   ^
Old Thu, Aug-24-17, 08:52
Zuleikaa Zuleikaa is offline
Finding the Pieces
Posts: 17,049
 
Plan: Mishmash
Stats: 365/308.0/185 Female 66
BF:
Progress: 32%
Location: Maryland, US
Default

Vitamin D Levels and Risk for Pancreatic Cancer

Researchers at the University of California, San Diego School of Medicine are reporting that living in a city with lots of cloud cover may be associated with risk for pancreatic cancer.

The report was recently published in the Journal of Steroid Biochemistry and Molecular Biology and stated that pancreatic cancer rates are highest in countries with the least amount of sunlight. Low sunlight levels were due to a combination of heavy cloud cover and high latitude.1

Researchers analyzed the association between cloud-adjusted ultraviolet B (UVB) irradiance and age-standardized incidence rates of pancreatic cancer. They found that the lower the cloud-adjusted UVB irradiance, the higher the incidence rate of pancreatic cancer.

“There was 8 times higher age-adjusted incidence rate of cancer in countries with the lowest solar UVB radiance compared to countries with the highest,” said lead study author Cedric Garland, DrPH, who is an adjunct professor in the Department of Family Medicine and Public Health and member of UC San Diego Moores Cancer Center, San Diego.

“Such a high hazard ratio when found in epidemiology almost always denotes causation by the factor of interest. It is similar to that for smoking and lung cancer.”

He and his colleagues studied data from more than 100 countries, taking into account international differences and possible confounders, such as alcohol consumption, obesity, and smoking.

Garland and his team have previously shown that sufficient levels of a metabolite of vitamin D in the serum, known as 25-hydroxyvitamin D was associated with substantially lower risk of breast and colorectal cancer.

The current paper is the first to implicate vitamin D deficiency with pancreatic cancer. He said these findings have clinical implications for oncologists.

“25-hydroxyvitamin D (25(OH)D) will prevent many future malignancies and definitely is associated with better survival of patients with breast, colorectal, and pancreatic cancer. So oncologists should always measure the serum 25(OH)D and raise it to no less than 80 ng/ml to 90 ng/ml in their patients with any of these cancers,” Garland told Cancer Therapy Advisor.

http://www.cancertherapyadvisor.com...article/414067/
Reply With Quote
  #1659   ^
Old Thu, Aug-24-17, 09:06
Zuleikaa Zuleikaa is offline
Finding the Pieces
Posts: 17,049
 
Plan: Mishmash
Stats: 365/308.0/185 Female 66
BF:
Progress: 32%
Location: Maryland, US
Default

I went looking because when my cousin was diagnosed with pancreatic cancer a few years ago I injected him with 1.2M I.U.s of D3 and his cancer went into remission for 4-5 months on that one shot. I had sent him more ampules but he never used them.

He's in end stage now.

*****
My nephew with kidney cancer also went into remission on high dose D3 as well. He went from being bedridden, got out of bed and was walking and biking. But he also stopped taking the doses...his doctors knew medicine and cancer better and they knew what to do without interference from a deranged aunt

He passed away last year. It seems that after he stopped the D3 doses his cancer got more aggressive.

I always wondered what would have happened if they had continued the injections.

****
I know about and think I've mentioned about a woman my cousin met who had breast cancer, had somehow seen the info sheet I put together on vitamin D3, injected herself with D3 for a year(?) and her breast cancer went into remission and gradually shrunk and was cured.


The Incidental Use of High-Dose Vitamin D3
in Pancreatic Cancer


http://online.liebertpub.com/doi/pd.../crpc.2016.0003

Last edited by Zuleikaa : Thu, Aug-24-17 at 09:18.
Reply With Quote
  #1660   ^
Old Thu, Aug-31-17, 06:02
Zuleikaa Zuleikaa is offline
Finding the Pieces
Posts: 17,049
 
Plan: Mishmash
Stats: 365/308.0/185 Female 66
BF:
Progress: 32%
Location: Maryland, US
Default

Vitamin D is closely linked to the clinical courses of herpes zoster: From pathogenesis to complications.

Vitamin D is renowned for its pleiotropic effects, including but not limited to bone integrity, and it has assumed an important role in the current research era. As vitamin D receptors are present in a variety of human tissues, particularly immune cells, the immunomodulatory potential of vitamin D cannot be overemphasized. Herpes zoster, which presents as grouped cutaneous vesicles over dermatomes or visceral/central nervous system infection in its severe form, has a higher incidence in immune-suppressed patients. Considering the importance of vitamin D in host immunity, we hypothesize that vitamin D acts as an effect-modifier for the entire herpes zoster spectrum with regard to disease susceptibility, manifestation, efficacy of pharmacologic management, and emergent complications during treatment. Moreover, the possibility exists that vitamin D might affect the course of postherpetic neuralgia. In line with this theory, we comprehensively searched the existing herpes zoster literature and provided important insight into the relationship between the disease courses of herpes zoster and vitamin D.

Copyright © 2015 Elsevier Ltd. All rights reserved.
Reply With Quote
  #1661   ^
Old Thu, Aug-31-17, 06:04
Zuleikaa Zuleikaa is offline
Finding the Pieces
Posts: 17,049
 
Plan: Mishmash
Stats: 365/308.0/185 Female 66
BF:
Progress: 32%
Location: Maryland, US
Default

Shingles and vitamin D

Summary: Vitamin D/UV probably treats shingles
•Shingles worse with low vitamin D, low UV, high latitude, and winter
•Treating shingles with Vitamin D or UV lowers the pain
•Treating shingles with Vitamin D almost eliminates risk of recurrence
•Vitamin D has even been patented to help with shingles
A patent is always a good sign that it probably works

https://www.vitamindwiki.com/Shingles+and+vitamin+D
Reply With Quote
  #1662   ^
Old Thu, Aug-31-17, 06:10
Zuleikaa Zuleikaa is offline
Finding the Pieces
Posts: 17,049
 
Plan: Mishmash
Stats: 365/308.0/185 Female 66
BF:
Progress: 32%
Location: Maryland, US
Default

Vitamin D To Prevent Herpes Outbreaks
By Miguel Gonzalez, MD, FACP, FCCP

Vitamin D Boosts Immune System



Using Vitamin D to prevent herpes is not a new concept. Studies involving vitamin D have shown that this nutrient plays a key role in optimizing immune system function. A healthy immune system helps fight viruses including the herpes virus, as well as many other infections including colds and flu and chronic diseases like diabetes, heart diseases and cancer. Vitamin D seems to stimulate the production of certain blood cells that play a key role in the health of the immune system. Vitamin D also coordinates the expression of several genes not previously believed to be part of the vitamin D pathway. These genes may also be involved in additional infection fighting pathways.

Prevent Herpes Outbreaks with Vitamin D

Not only is Vitamin D a nutrient, but it is also an important hormone produced by our bodies. Becausethumb_P1010092_1024 only a few foods naturally contain vitamin D, a variety of foods and products have been fortified with Vitamin D. The very best source of vitamin D is from the sun, hence its name “the sunshine vitamin”. Shockingly, the far vast majority of North Americans are vitamin D deficient. This deficiency is linked with close to one hundred health concerns and more is being found about this wonder vitamin each year. Vitamin D may also be helpful in managing the herpes virus, by boosting the immune system and reducing the body’s inflammatory reactions to herpes virus infections.

Vitamin D and Herpes Virus Infections

A study featured in the July 2011 issue of “Clinical and Experimental Rheumatology”, revealed that Vitamin D3 improves herpes virus infection and inflammation in animal subjects. The scientists from Ajou University Institute for Medical Sciences, Korea also noted that vitamin D fought against herpes virus by down-regulating the expression of some receptors called TLR and cytokines, proteins that play a key role in inflammatory processes.

Vitamin D and Herpes Zoster

Shingles or herpes zoster occurs when the virus that causes chickenpox reactivates in your body. This virus reactivation can be triggered by many factors such as diseases, stress, diet or any other condition that weakens the immune system. Post-herpetic neuralgia is the most common symptom of shingles. Post-herpetic neuralgia pain that lasts for more than a month, and sometimes many months after a shingles outbreak has occurred. A study published in December 2009 in “Medical Hypothesis”, showed that post-herpetic neuralgia may benefit from vitamin D. In this study, researchers used high doses of vitamin D applied topically, although they suggested that oral vitamin D may work as well.

Skin exposed to the sun for half an hour, will produce roughly 10,000 IU of vitamin D in your body, which helps to optimize your vitamin D status. However, sun can also trigger the reactivation of the herpes virus. Using sunscreen will block 90% of the vitamin D production, so that doesn’t help. In order to avoid a herpes outbreak caused by too sun exposure or just to keep the herpes virus in check by maintaining optimal Vitamin D levels, you should consider using Vitamin D supplements, either in tablet, liquid or topical form. Generally speaking, you should not take more than 10,000 IU vitamin D per day. Also, be sure to take Vitamin D that also has Vitamin K1 and K2 for better absorption. Talk to your healthcare provider to find out more about the optimal dose needed to prevent or manage herpes virus infections.

https://www.mynaturalmd.com/vitamin...rpes-outbreaks/
Reply With Quote
  #1663   ^
Old Thu, Aug-31-17, 06:34
Zuleikaa Zuleikaa is offline
Finding the Pieces
Posts: 17,049
 
Plan: Mishmash
Stats: 365/308.0/185 Female 66
BF:
Progress: 32%
Location: Maryland, US
Default

Risk factors for herpes zoster reactivation in maintenance hemodialysis patients.

Chao CT1, Lai CF, Huang JW.



Author information


Abstract

OBJECTIVE:

Herpes zoster (HZ) reactivation is common in immunocompromised patients. Advanced renal failure is also reportedly associated with impairment of cellular immunity. There is not any study yet assessing risk factors of HZ reactivation in hemodialysis patients.

METHODS:

All patients undergoing maintenance hemodialysis for more than 3 months and who developed HZ between 2000/01/01 and 2009/12/31 in a tertiary referral medical center were identified, and matched 1:1 to hemodialysis patients without HZ by age and gender. Multivariate-adjusted conditional logistic regression model was constructed to determine possible risk factors.

RESULTS:

Out of a total of 126 maintenance hemodialysis patients (65.3% female), 63 belonged to the HZ reactivation group and 63 to the age/sex matched control patients. Conditional logistic regression model linked corticosteroid use with heightened risk (odds ratio [OR] 20.2, 95% confidence interval [CI] 3.5-125.6; p=0.002), while iron therapy and 1α-hydroxylated vitamin D were associated with significantly lower likelihood of developing HZ (OR 0.12, 95%CI 0.0-0.6; p=0.01, and OR 0.06, 95% CI 0.0-0.4; p=0.005 respectively).

CONCLUSIONS:

Use of iron preparations and 1α-hydroxylated vitamin D is potentially associated with less risk of developing HZ reactivation in maintenance hemodialysis patients.

https://www.ncbi.nlm.nih.gov/pubmed...l+herpes+zoster
Reply With Quote
  #1664   ^
Old Sun, Sep-03-17, 07:51
Zuleikaa Zuleikaa is offline
Finding the Pieces
Posts: 17,049
 
Plan: Mishmash
Stats: 365/308.0/185 Female 66
BF:
Progress: 32%
Location: Maryland, US
Default

Albuminuria Reduction after High Dose of Vitamin D in Patients with Type 1 Diabetes Mellitus: A Pilot Study.

BACKGROUND:
Some studies suggest an association between diabetic kidney disease (DKD) and vitamin D (VD), but there is no data about the effect of high dose of VD on DKD in type 1 diabetes mellitus (T1DM). Our pilot study aims to evaluate albuminuria reduction in patients with T1DM supplemented with high dose of VD.
METHODS:
22 patients received doses of 4,000 and 10,000 IU/day of cholecalciferol for 12 weeks according to patient's previous VD levels. They were submitted to continuous glucose monitoring system, 24 hours ambulatory blood pressure monitoring and urine albumin-to-creatinine ratio before and after VD supplementation.
RESULTS:
There was a reduction of DKD prevalence at the end of the study (68 vs 32%; p = 0.05), with no changes on insulin doses, glycated hemoglobin, glycemic variability and blood pressure values. A correlation between percentage variation of VD levels (ΔVD) and albuminuria at the end of the study was presented (r = -0.5; p < 0.05). Among T1DM patients with DKD at the beginning of the study, 8/13 (62%) had their DKD stage improved, while the other five ones (38%) showed no changes (p < 0.05).
CONCLUSION:
Our pilot study suggests an association between VD high dose supplementation, lower prevalence and improvement in stages of DKD in T1DM.

https://www.ncbi.nlm.nih.gov/pubmed/28855892
Reply With Quote
  #1665   ^
Old Sun, Sep-03-17, 07:54
Zuleikaa Zuleikaa is offline
Finding the Pieces
Posts: 17,049
 
Plan: Mishmash
Stats: 365/308.0/185 Female 66
BF:
Progress: 32%
Location: Maryland, US
Default

A vitamin D protocol post-liver transplantation.
Grant C1,2.
Author information


Abstract
BACKGROUND AND PURPOSE:
Adults with compromised liver function are inherently deficient and especially vulnerable to the consequences of vitamin D deficiency. Consequences of vitamin D deficiency include liver disease progression, infection, and graft failure. A vitamin D supplementation protocol is proposed to systematically optimize serum vitamin D levels according to guidelines in both pre- and post-liver transplanted patients.
METHODS:
This quasiexperimental study included a sample of N = 45 post-liver transplanted patients taking daily cholecalciferol (vitamin D3) 2500 units for 12~weeks, with a pre- and post-lab measure of serum 25-hydroxyvitamin D levels at a large academic facility.
CONCLUSIONS:
Seventy-eight percent of patients reached minimum guideline levels using the protocol with an average increase of serum vitamin D of 13.8~ng/mL. Long-term outcomes of clinical significance may include decreased incidence of acute T-cell-mediated graft rejection and infections in the immunocompromised patient.
IMPLICATIONS FOR PRACTICE:
Optimizing vitamin D in vulnerable patient populations such as chronic liver disease and the immunosuppressed posttransplanted patient has the potential to curtail complications of vitamin D deficiency. As a result, nurse practitioners employing a vitamin D protocol can create a favorable impact on patient quality of life, safety, and healthcare spending.
©2017 American Association of Nurse Practitioners.

https://www.ncbi.nlm.nih.gov/pubmed/28840965
Reply With Quote
Reply


Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

vB code is On
Smilies are On
[IMG] code is On
HTML code is Off



All times are GMT -6. The time now is 08:49.


Copyright © 2000-2024 Active Low-Carber Forums @ forum.lowcarber.org
Powered by: vBulletin, Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.